Affiliation:
1. Department of Physics, Faculty of Sciences, Aydın Adnan Menderes University, Aydın, Turkey
Abstract
Background:
Cancer is one of the diseases affecting a large population worldwide and
resulting in death. Finding new anti-cancer drugs that are target-focused and have low toxicity is
of great importance.
Objective:
This study aimed to investigate the effects of vic-dioxime derivatives carrying hydrazone
group and its Zn(II) complex on cancer using molecular docking, bioactivity and quantum
chemical calculations.
Methods:
Molecular docking studies were performed on epidermal growth factor receptor and
vascular endothelial growth factor receptor 2 target proteins. Furthermore, molecular geometry
was performed, and the frontier molecular orbitals, Mulliken charges and molecular electron density
distribution were evaluated using density functional theory. Also, the bioactivity parameters
of the compounds were evaluated, and ADME analysis was performed using web-based tools.
Results:
Higher binding affinity was observed for Zn(II) complex with target proteins vascular
endothelial growth factor receptor 2 and against epidermal growth factor receptor when compared
with LH2. Only the Zn(II) complex against the epidermal growth factor receptor had ligand efficiency
and fit quality in the valid range. Furthermore, LH2 has the most potent electrophilic ability
(acceptor) among other compounds. Moreover, both LH2 and Zn(II) complexes strongly satisfy
Lipinski’s rule of five.
Conclusion:
In conclusion, these novel compounds, especially Zn(II) complex, can be new candidates
for anticancer drug development studies which are target-focused and have low toxicity.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Molecular Medicine,General Medicine